EMA Reviews Depression, Anxiety Drug Over Adverse Effects

02 Nov 2026 0 comments

Deanxit (flupentixol-melitracen) is under review after reports of movement disorders and memory and thinking problems, with some symptoms persisting after treatment was stopped.
Medscape News Europe

Source: Medscape Neurology Published 02 Nov 2026 Imported 02 Nov 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment